Cenedella.de

Patient Advocate since 1977.


Leave a comment

Cannabis Sales Impact Big Pharma Profits

Medical Cannabis Could Take a Big Bite Out of Pharmaceutical Sales

  • Cannabis is an effective treatment for conditions including chronic pain, post-traumatic stress disorder (PTSD), sleep disorders, anxiety, epilepsy, nerve pain, chemotherapy-induced nausea and vomiting, Tourette’s Syndrome, and glaucoma. *
  • Americans spent an estimated $40.1 billion on prescription medications in 2016 to treat these conditions, and expenditures are forecast to grow to more than $44.1 billion by 2019.
  • Three conditions which drove the highest prescription drug expenditures in 2016 were chronic pain ($14.3 billion), PTST ($10.6 billion), and sleep disorders ($6.13 billion).
  • Prescription drug use, most commonly associated with medical cannabis, falls an average of 11% in states with legalized medical cannabis.
  • If medical cannabis use were legalized nationally in 2016, an 11% decline in prescription drug use would have equated to an estimated $4.4 billion in reduced prescription drug spending, and an estimated $4.9 billion in 2019.
  • Between 2016 and 2020, the 11% reduction in prescription drug spending would be a combined $18.5 billion.
  • The impact that cannabis legalization will have on the pharmaceutical industry underscores why pharmaceutical companies have been so strongly opposed to the expansion of legal cannabis.  For example, Insys, maker of the opioid Fentanyl Subsys, funded the 2016 anti-cannabis legalization campaign in Arizona.  Insys’ financial support of the opposition helped defeat the initiative on election day.

* According to the National Academies of Science

Medical Cannabis Could Take a Big Bite Out of Pharmaceutical Sales

 


Leave a comment

Chris Driessen from ORGANA BRANDS — Celebrate commoditization and the birth of “Big Cannabis”

Celebrate commoditization and the birth of “Big Cannabis”

by Chris Driessen

I now buy legal cannabis by the ton. I negotiate the price of dried, ground marijuana as if it were just another commodity…because it is. Cannabis is simply an amazing agricultural commodity and precious raw material input– dropped into a not-so-complicated equation, designed to produce profit.

Just two years ago I was paying some $2,000 a pound for world class marijuana. Now that price has fallen by two thirds and I pay roughly $600 a pound. This is great news for our purchasing department, but not so much for our wholesale prices. Alas, this was inevitable, it’s simple economics. It makes market expansion all the more critical. If you are not growing, you’re dying, or soon will be. More money in the market invites more competition, which motivates us to innovate, scale and ultimately find efficiencies in our processes.. or be chewed up by the competition.

At Organa Brands, I oversee an entire house of brands that makes everything from cannabis vaporizers to THC tablets, edibles and dabs, and even energy drinks. I expect that before long, our CBD products — many of which have no THC — will be stocked on shelves at convenience stores, gas stations, Costco and Walmart.

Fortunately, that’s where my experience lies. Before entering the world of cannabis, I had spent years as a printer salesman, selling millions of dollars of commercial printers to clients throughout the Rocky Mountain region. The commercial printing business is cutthroat, as any office manager with a decent sized copy machine will attest. The hardware is sold for the narrowest of margins, or even below cost, while the emphasis is put on the consumable commodity, which is the ink.

Seem familiar? If not, what kind of cellphone do you have? You likely got the phone on the cheap or even free, as long as you signed up for the lengthy service contract. Guess where the money is made?

There are purists who shun the idea that if (when) marijuana goes mainstream, it is a disaster. They believe it’s a cave-in to big capital, big corporations, to profiteers and all things sacred of this undoubtedly magical plant. I couldn’t disagree more. If we are to unlock and share the medicinal and wellness properties of cannabis, why not champion the professional distribution of our favorite plant? Why not embrace enterprise resource planning software platforms, hi-tech manufacturing techniques, tighter inventory controls, agricultural efficiencies and crisp profit-and-loss statements?

The best homage we can make to this amazing plant is to produce the finest cannabis oil possible, to place it in attractive, finely-tuned packaging, that is both alluring to adult consumers and childproof, and offer it to consumers nationwide. The greatest contribution I can give to this industry and this amazing plant is to make sure it finds its way into as many lives as possible. We can scale our businesses larger, scrutinize costs and expenses, pour over financial reports and become the solid start-up that transforms into a legacy company that withstands the ups and down of the business world.

I believe we should celebrate national cannabis brands because we are able to incorporate up-and-coming products and place their innovative oils, edibles and medicines into our nationwide distribution network that reaches some 1,200 dispensaries in 10 states (and counting). We should support and encourage each other to become a tribe of companies, a community of cannabis enthusiasts that collectively have the market power of “Big Cannabis”. While that name scares many, it simply means that our industry has “made it.” It means we are here to stay, that we withstood the test of time and government prohibition. We have found a permanent home in the world economy.

When people criticize what they fear is the “homogenization” of marijuana, I can only laugh. Is there any better way to celebrate diversity of brands and up-and-coming entrepreneurial know-how than to offer a launch pad to those superior cannabis products? A launch pad that guarantees their product can be sold from Boston to Berlin, from San Francisco to Sydney?

It has been this same process of consolidation, which is a natural evolution in any maturing industry, that led the O.penVAPE team to look beyond vape pens and incorporate a whole new range of products, and a whole new range of possibilities. That’s why earlier this year we rebranded as Organa Brands — literally a house of brands.

For years, the company where I work was known for its O.penVAPE pens. We sold some 6 million of our cartridges and earned a strong customer following and loyalty with budtenders nationwide. Was that the result of some fortuitous “lucky break” or the natural result of dozens, then hundreds of employees working weekends, staying late and attempting to find a route to success in the highly competitive cannabis industry? I’ll let you answer that one, because I already know.

Our downtown Denver corporate office looks more like a tech startup in Silicon Valley than a mega cannabis conglomerate. We have trendy coffees that self-brew on demand, organic snacks and the requisite office pets and ping pong table. But don’t let the laid back atmosphere or tunes playing on the Sonos fool you. Our office is stocked with brilliant minds ready to go toe-to-toe with Big Tobacco, Big Alcohol and Big Pharma. We relish the opportunity to measure up against other, more mature industries. To do that we must first pass through the inevitable commoditization of our products, work with the compression of profit margins and weather the oncoming storm of consolidation.

I don’t make any medical or health claims about cannabis, but I know that a deep feeling of wellness and peace accompanies the cannabis products we produce. Every day, I receive letters of thanks. If this deep wellspring of consumer support leads to the nation’s first national chain of dispensaries, or million-acre cultivation facility, or a multinational consumer products cannabis company, I say we should all celebrate.


Leave a comment

Dr. Franjo Grotenhermen – HERO!

Solidarity for abandoned cannabis patients.

Dr. med. Franjo Grotenhermen Employee of the nova Institute, Chairman of the Cannabis Association as Medicine (ACM)
Dr. med. Franjo Grotenhermen, photo: Archive

 

The well-known physician and chairman of the Cannabis Association as a medicine (ACM) Dr. Franjo Grotenhermen has made a moving decision. Although certain positive aspects could be felt in parts through the enacted cannabis-as-medicine law, there would be enough problems in the entire treatment area, which now led to a drastic measure. During the ACM Annual General Meeting in Frankfurt on May 12, 2017, the medical doctor, who has been advocating medical medicine for many years, declares his decision not to eat any food for the next one to two weeks as a result of solidarity with the many cannabis patients left alone.
Doctor Franjo Grotenhermen joins the hunger strike.

 


Dr. Franjo Grotenhermen at the ACM Annual General Meeting 2017 explains hunger strike.

 

The drug policy speakers of the parties were informed before Dr. Franjo Grotenhermen of the warnings – an honorary man.


Leave a comment

Leafly Launches German-Language Edition

Leafly German

Leafly.de is a medical cannabis information resource and knowledge portal

BERLIN–(BUSINESS WIRE)–Leafly, the world’s cannabis information resource, has arrived in Germany with the launch of www.Leafly.de, a German-language medical cannabis information resource and knowledge portal. The new German-language version of Leafly capitalizes on the expertise Leafly has cultivated over the past seven years as the world’s most visited cannabis website. As one of Leafly’s most prominent international ventures to date, Leafly.de formalizes Leafly’s commitment to providing reliable, accessible information about cannabis to people in Germany and around the world.

Leafly’s arrival in Germany was celebrated this week at a launch event in Berlin. Medical cannabis patients and representatives from the media joined Leafly’s editorial team to participate in a lively exchange on the topic of medical cannabis. Leafly’s inaugural German-language editorial team includes a range of healthcare experts, including science journalists, researchers, and a doctor. The launch of Leafly.de follows Leafly’s appearance at Berlin’s annual Hanfparade last year. Hanfparade is the largest pro-cannabis and hemp event in Germany that has taken place every year since 1997.

Leafly is the world’s leading cannabis website and mobile application, generating more than 12 million unique visits per month and more than 60 million page views. Approximately 70 percent of Leafly’s traffic comes from the United States and 30 percent originates from international destinations, including Australia, Canada, France, Germany, Spain, South Africa, and the United Kingdom. With the launch of Leafly.de, Leafly is now available in English, Spanish, French, and German.

Leafly.de initially will focus on several subject areas of immediate concern to medical cannabis patients and their healthcare providers. Visitors to the site can learn more about Germany’s recent medical cannabis reforms, how those changes affect them, and how they can become medical cannabis patients. News and analysis regarding medical cannabis laws and the supply of licensed cannabis-derived medicines will also be covered. In addition, Leafly.de will serve as a guide for doctors, pharmacists, and other medical professionals to learn more about the medical use of cannabis for conditions such as chronic pain.

Leafly.de taps into Leafly’s global coverage of cannabis science, medicine, and patient trends. Visitors will find the latest scientific research, patient surveys, and breaking news. The site also features a comprehensive cannabis dictionary featuring information from the anatomy of the cannabis plant to breaking policy news in Germany. The depth of Leafly’s expertise is why millions of people around the world visit Leafly every month for cannabis news and information.

Visit http://www.Leafly.de for more information.

About Leafly

As the world’s largest cannabis information resource, Leafly’s mission is to help patients and consumers make informed choices about cannabis and to empower cannabis businesses to attract and retain loyal customers through advertising and technology services. Learn more at http://www.leafly.com or download the five-star rated Leafly mobile app through Apple’s App Store or Google Play.

Original press release: http://www.businesswire.com/news/home/20170512005681/en/Leafly-Launches-German-Language-Edition

 


Leave a comment

Maricann secures $42.5 million for German Grow Facility – from Green Streaming Finance Company of Canada éh

Toronto, Ontario–(Newsfile Corp. – May 4, 2017) – Maricann Group Inc. (CSE: MARI) (Maricann or the ‘Company’) is pleased to announce that Maricann has secured $42,500,000 in non-dilutive financing to further expand production in Germany.

The $42,500,000 non-dilutive financing comes from The Green Streaming Finance Company of Canada Inc., a Vancouver-based company that provides non-equity financing solutions for cannabis producers. The streaming payment will be made in return for the right to purchase 20% of production at an all in cost +10% from expansion funded by Green Streaming in Germany.

We are pleased to be funding Maricann and their expansion efforts in Germany. This is a win-win relationship for Maricann and Green Streaming Finance, with no dilution to Maricann shareholders and a stable, reliable, renewable stream of revenue to Green Stream Finance from a proven producer of medicinal cannabis.

donald-mcinnesDonald McInnes, founder of Green Streaming Finance

Under the terms of the agreement, Maricann will receive investment in two tranches, $15,000,000 and a $27,500,000. This financing will fully fund the planned 150,000 sq. ft (13,935 square meters) expansion of cultivation operations in its Ebersbach Facility and an additional 250,000 sq. ft. (23,255 sq. m.) of expansion in a two tiered cultivation plan, as well as an outdoor hemp farm from which Maricann will derive high CBD content active pharmaceutical ingredients. The Ebersbach facility (West of Dresden), is a former Cargill plant constructed 20 years ago at a cost of 80 million EUR at that time. The facility is comprised of multiple individual clean rooms that are ideal for cultivation of cannabis.

The Ebersbach facility offers Maricann a significant advantage in cost of overall construction and speed to market. The infrastructure for cultivation of cannabis in an indoor secured environment is already in place. We simply need to add the fertigation system, lights and benches for growing, and then can be operational.

ben ward maricann groupBenjamin Ward, CEO

Our competitors are spending north of $70,000,000 CAD for facilities with less than 1/3 the footprint of our Ebersbach location. To construct a similar facility today, the estimated cost would be over 120 million EUR. Maricann entered into a reservation agreement to purchase the facility for a total price of 3,410,000 EUR at closing.

About Maricann Group Inc.

Maricann is a vertically integrated producer and distributor of marijuana for medical purposes. The company was founded in 2013 and is based in Langton, Ontario, where it operates a medicinal cannabis cultivation, extraction and distribution business under federal licence from the Government of Canada. Maricann, which has federal licences to cultivate, process and distribute cannabis, services a patient base with more than 8,000 total registered patients since inception. Maricann is currently undertaking an expansion of its cultivation and support facilities in Canada in a fully funded 217,000 sq. ft. (20,159 sq. m), to support existing and future patient growth. Maricann GmbH is a 95% owned subsidiary of Maricann Netherlands BV, a 100% wholly owned subsidiary of Maricann Group Inc.

Maricann Milestones

  • April 2013, Maricann Inc. is founded in Langton, Ontario, a well-established agricultural region in southwestern Ontario
  • March 2014, Maricann Inc. obtains its Health Canada licence to cultivate plants
    December 2014, Maricann Inc. obtains its Health Canada licence to sell dried cannabis
  • January 2015, first dried cannabis sale
  • September 2016, Maricann Inc. earns its Health Canada licence to sell cannabis extracts
  • October 2016, first sale of extracted cannabis
  • December 2016, Maricann Inc. raises $22.5 million in private capital
  • January 2017, commences sale of clones
  • February 2017, Maricann Inc. raises $10 million in private capital
  • April 24, 2017, first day of trading on the CSE
  • April 28, 2017, announces Advisory Board of German subsidiary.

For more information about Maricann please visit our website at www.maricann.ca.

Contact Information

Shawn Alexander
VP Investor Relations
salexander@maricann.ca

Corporate Headquarters:
Maricann Group Inc. (C.MARI)
845 Harrington Court, Unit 3
Burlington Ontario L7N 3P3
Canada

Dial Toll Free in North America:
1.844.Maricann (627.4226)

Original press release: http://www.accesswire.com/461841/Maricann-Secures-42500000-Non-Dilutive-Financing-for-Further-German-Expansion


2 Comments

Germany: Cultivation License, tender information

Germany-Bonn: medical equipment, pharmaceuticals and personal care products

http://ted.europa.eu/udl?uri=TED:NOTICE:131987-2017:TEXT:DE:HTML&src=0#id1042115-III.

2017 / S 070-131987

contract notice

Supplies

Directive 2014/24 / EU

Section I: Contracting authorities

I.1)Name and addresses

Federal Institute for Drugs and Medical Devices (BfArM)
Kurt-Georg-Kiesinger-Allee 3
Bonn
53175
Germany
Contact: Bundesinstitut für Arzneimittel und Medizinprodukte, Frau Stefanie Vogt
Phone: +49 228-2074124
E-Mail: Z122@bfarm.de
Fax : +49 228-2074352
NUTS Code: DEA22Internet address (es):Main address: http://www.bfarm.de

I.2)Common procurement strategy

I.3) Address from whichfurther information can be obtained:

The order documents are available free of charge for full and complete direct access at: https://www.evergabe-online.de/tenderdetails.html?id=156533
Further information can be obtained from the above-mentioned contact point (s)
Tenders or requests to participate must be submitted to the above mentioned contact point (s)

I.4)Type of the contracting authority

Ministry or other central or federal authority, including regional or local subdivisions

I.5)Main activity (s)

health

Section II: Subject

II.1)Scope of procurement

II.1.1) Titleattributed to the contract:

Cultivation, processing, storage, packaging and delivery of cannabis for medical purposes.

Reference number of the contract notice: 2281-1713

II.1.2) Mainterms of the sale or purchase:

33000000

II.1.3)Type of contract

Supplies

II.1.4)Short description:

Cultivation, further processing, storage, packaging and delivery of cannabis for medical purposes in a secure inhouse plantation in Germany.

II.1.5)Estimated total value

II.1.6)Information about lots

Division of the contract into lots: yes
Offers are possible for all lots
Maximum number of lots to be awarded to a contracting authority: 7
II.2)Description

II.2.1)Title attributed to the contract:

Cultivation, processing, storage, packaging and delivery of cannabis for medical purposes in a secure inhouse plantation in Germany

Lot No: 1

II.2.2)Additional CPV code (s)

03117120

II.2.3)Place of performance

NUTS code: DEA22

II.2.4)Description of the sourcing:

Cultivation, processing, storage, packaging and delivery of cannabis (type 1): delivery period 2019 to 2022, delivery volume approx. 200 kg per year.

II.2.5)Award criteria

The price is not the only supplementary criterion; All criteria are listed in the procurement documents only
II.2.6)Estimated value

II.2.7)Duration of the contract or framework agreement or of the dynamic purchasing system

Duration in months:
This contract can be extended: no

II.2.9)Indication about the number of operators who will be invited to tender or to participate

Planned number of candidates: 10
Objective criteria for selecting the limited number of applicants:

(A) references to earlier contracts awarded by the applicant for the cultivation, processing and delivery of cannabis for medical purposes with a delivery quantity of at least 50 kg per reference for the last 3 years. A reference to an order for the cultivation, processing and delivery of medical cannabis shall also apply if, with the consent of the competent authority in the country concerned, the tenderer submits directly to this body in accordance with Article 23 of the 1961 Unified Agreement on Narcotic Drugs A variety of different performance receivers have been delivered and the total delivery quantity has amounted to at least 50 kg. The applicant will receive 10 points (maximum 40 points) per 50 kg of delivery (whether in the context of one or more orders).

(B) references to the cultivation, processing and supply of medicinal plants (without cannabis) with a delivery quantity of at least 50 kg per reference over the last three years (whether in the case of a single order or several contracts) Points (maximum score 20 points).

C) If more than 10 applicants receive a score of more than 60, the selection is based on the highest total delivery quantity in the last three years according to lit. A), according to lit. b).

D) If fewer than 10 applicants receive a score of 60, the selection is based on the highest total delivery quantity in the last three years according to lit. A), according to lit. b).

II.2.10)Information about variants / alternative offers

Variants / alternative offers are permitted: no

II.2.11) Informationon options

Options: no
II.2.12)Information about electronic catalogs

II.2.1)Information about European Union funds

The contract is linked to a project and / or program financed by the EU: no
II.2.1)Additional information
II.2)Description

II.2.1)Title attributed to the contract:

Cultivation, further processing, storage, packaging and delivery of cannabis for medical purposes in a secure inhouse plantation in Germany.

Lot No: 2

II.2.2)Additional CPV code (s)

03117120

II.2.3)Place of performance

NUTS code: DEA22

II.2.4)Description of the sourcing:

Cultivation, processing, storage, packaging and delivery of cannabis (type 1): delivery period 2019 to 2022, delivery volume approx. 200 kg per year.

II.2.5)Award criteria

The price is not the only supplementary criterion; All criteria are listed in the procurement documents only
II.2.6)Estimated value

II.2.7)Duration of the contract or framework agreement or of the dynamic purchasing system

Duration in months:
This contract can be extended: no

II.2.9)Indication about the number of operators who will be invited to tender or to participate

Planned number of candidates: 10
Objective criteria for selecting the limited number of applicants:

(A) references to earlier contracts awarded by the applicant for the cultivation, processing and delivery of cannabis for medical purposes with a delivery quantity of at least 50 kg per reference for the last 3 years. A reference to an order for the cultivation, processing and delivery of medical cannabis shall also apply if, with the consent of the competent authority in the country concerned, the tenderer submits directly to this body in accordance with Article 23 of the 1961 Unified Agreement on Narcotic Drugs A variety of different performance receivers have been delivered and the total delivery quantity has amounted to at least 50 kg. The applicant will receive 10 points (maximum 40 points) per 50 kg of delivery (whether in the context of one or more orders).

(B) references to the cultivation, processing and supply of medicinal plants (without cannabis) with a minimum quantity of 50 kg per reference for the last three years (whether in the case of a single order or several contracts): the applicant receives 5 points per 50 kg delivery (A maximum of 20 points).

C) If more than 10 applicants receive a score of more than 60, the selection is based on the highest total quantity delivered in the last three years according to lit. A), according to lit. b).

II.2.10)Information about variants / alternative offers

Variants / alternative offers are permitted: no

II.2.11) Informationon options

Options: no
II.2.12)Information about electronic catalogs

II.2.1)Information about European Union funds

The contract is linked to a project and / or program financed by the EU: no
II.2.1)Additional information
II.2)Description

II.2.1)Title attributed to the contract:

Cultivation, further processing, storage, packaging and delivery of cannabis for medical purposes in a secure inhouse plantation in Germany.

Lot No: 3

II.2.2)Additional CPV code (s)

03117120

II.2.3)Place of performance

NUTS code: DEA22

II.2.4)Description of the sourcing:

Cultivation, processing, storage, packaging and delivery of cannabis (type 1): delivery period 2019 to 2022, delivery volume approx. 200 kg per year.

II.2.5)Award criteria

The price is not the only supplementary criterion; All criteria are listed in the procurement documents only
II.2.6)Estimated value

II.2.7)Duration of the contract or framework agreement or of the dynamic purchasing system

Duration in months:
This contract can be extended: no

II.2.9)Indication about the number of operators who will be invited to tender or to participate

Planned number of candidates: 10
Objective criteria for selecting the limited number of applicants:

(A) references to earlier contracts awarded by the applicant for the cultivation, processing and delivery of cannabis for medical purposes with a delivery quantity of at least 50 kg per reference for the last 3 years. A reference to an order for the cultivation, processing and delivery of medical cannabis shall also apply if, with the consent of the competent authority in the country concerned, the tenderer submits directly to this body in accordance with Article 23 of the 1961 Unified Agreement on Narcotic Drugs A variety of different performance receivers have been delivered and the total delivery quantity has amounted to at least 50 kg. The applicant will receive 10 points (maximum 40 points) per 50 kg of delivery (whether in the context of one or more orders).

(B) references to the cultivation, processing and supply of medicinal plants (without cannabis) with a minimum quantity of 50 kg per reference over the last three years (whether in the context of one or more contracts): The applicant shall be supplied per 50 kg of delivery 5 points (maximum score 20 points).

C) If more than 10 applicants receive a score of more than 60, the selection is based on the highest total delivery quantity in the last three years according to lit. A), according to lit. b).

D) If fewer than 10 applicants receive a score of 60, the selection is based on the highest total delivery quantity in the last three years according to lit. A), according to lit. b).

II.2.10)Information about variants / alternative offers

Variants / alternative offers are permitted: no

II.2.11) Informationon options

Options: no
II.2.12)Information about electronic catalogs

II.2.1)Information about European Union funds

The contract is linked to a project and / or program financed by the EU: no
II.2.1)Additional information
II.2)Description

II.2.1)Title attributed to the contract:

Cultivation, further processing, storage, packaging and delivery of cannabis for medical purposes in a secure inhouse plantation in Germany.

Lot No: 4

II.2.2)Additional CPV code (s)

03117120

II.2.3)Place of performance

NUTS code: DEA22

II.2.4)Description of the sourcing:

Cultivation, processing, storage, packaging and delivery of cannabis (type 1): delivery period 2020 to 2022, delivery volume approx. 200 kg per year.

II.2.5)Award criteria

The price is not the only supplementary criterion; All criteria are listed in the procurement documents only
II.2.6)Estimated value

II.2.7)Duration of the contract or framework agreement or of the dynamic purchasing system

Duration in months:
This contract can be extended: no

II.2.9)Indication about the number of operators who will be invited to tender or to participate

Planned number of candidates: 10
Objective criteria for selecting the limited number of applicants:

(A) references to earlier contracts awarded by the applicant for the cultivation, processing and delivery of cannabis for medical purposes with a delivery quantity of at least 50 kg per reference for the last 3 years. A reference to an order for the cultivation, processing and delivery of medical cannabis shall also apply if, with the consent of the competent authority in the country concerned, the tenderer submits directly to this body in accordance with Article 23 of the 1961 Unified Agreement on Narcotic Drugs A variety of different performance receivers have been delivered and the total delivery quantity has amounted to at least 50 kg. The applicant will receive 10 points (maximum of 40 points) for each 50 kg of delivery (whether for one or more orders).

(B) references to the cultivation, processing and supply of medicinal plants (without cannabis) with a delivery quantity of at least 50 kg per reference over the last three years (whether in the case of a single order or several contracts) Points (maximum score 20 points).

C) If more than 10 applicants receive a score of more than 60, the selection is based on the highest total delivery quantity in the last three years according to lit. A), according to lit. b).

D) If fewer than 10 applicants receive a score of 60, the selection is based on the highest total delivery quantity in the last three years according to lit. A), according to lit. b).

II.2.10)Information about variants / alternative offers

Variants / alternative offers are permitted: no

II.2.11) Informationon options

Options: no
II.2.12)Information about electronic catalogs

II.2.1)Information about European Union funds

The contract is linked to a project and / or program financed by the EU: no
II.2.1)Additional information
II.2)Description

II.2.1)Title attributed to the contract:

Cultivation, further processing, storage, packaging and delivery of cannabis for medical purposes in a secure inhouse plantation in Germany.

Lot No: 5

II.2.2)Additional CPV code (s)

03117120

II.2.3)Place of performance

NUTS code: DEA22

II.2.4)Description of the sourcing:

Cultivation, processing, storage, packaging and delivery of cannabis (type 1): delivery period 2020 to 2022, delivery volume approx. 200 kg per year.

II.2.5)Award criteria

The price is not the only supplementary criterion; All criteria are listed in the procurement documents only
II.2.6)Estimated value

II.2.7)Duration of the contract or framework agreement or of the dynamic purchasing system

Duration in months:
This contract can be extended: no

II.2.9)Indication about the number of operators who will be invited to tender or to participate

Planned number of candidates: 10
Objective criteria for selecting the limited number of applicants:

(A) references to earlier contracts awarded by the applicant for the cultivation, processing and delivery of cannabis for medical purposes with a delivery quantity of at least 50 kg per reference for the last 3 years. A reference to an order for the cultivation, processing and delivery of medical cannabis shall also apply if, with the consent of the competent authority in the country concerned, the tenderer submits directly to this body in accordance with Article 23 of the 1961 Unified Agreement on Narcotic Drugs A variety of different performance receivers have been delivered and the total delivery quantity has amounted to at least 50 kg. The applicant will receive 10 points (maximum of 40 points) for each 50 kg of delivery (whether for one or more orders).

(B) references to the cultivation, processing and supply of medicinal plants (without cannabis) with a delivery quantity of at least 50 kg per reference over the last three years (whether in the case of a single order or several contracts) Points (maximum score 20 points).

C) If more than 10 applicants receive a score of more than 60, the selection is based on the highest total delivery quantity in the last three years according to lit. A), according to lit. b).

D) If fewer than 10 applicants receive a score of 60, the selection is based on the highest total delivery quantity in the last three years according to lit. A), according to lit. b).

II.2.10)Information about variants / alternative offers

Variants / alternative offers are permitted: no

II.2.11) Informationon options

Options: no
II.2.12)Information about electronic catalogs

II.2.1)Information about European Union funds

The contract is linked to a project and / or program financed by the EU: no
II.2.1)Additional information
II.2)Description

II.2.1)Title attributed to the contract:

Cultivation, further processing, storage, packaging and delivery of cannabis for medical purposes in a secure inhouse plantation in Germany.

Lot No: 6

II.2.2)Additional CPV code (s)

03117120

II.2.3)Place of performance

NUTS code: DEA22

II.2.4)Description of the sourcing:

Cultivation, processing, storage, packaging and delivery of cannabis (type 1): delivery period 2021 to 2022, delivery quantity approx. 200 kg per year.

II.2.5)Award criteria

The price is not the only supplementary criterion; All criteria are listed in the procurement documents only
II.2.6)Estimated value

II.2.7)Duration of the contract or framework agreement or of the dynamic purchasing system

Duration in months:
This contract can be extended: no

II.2.9)Indication about the number of operators who will be invited to tender or to participate

Planned number of candidates: 10
Objective criteria for selecting the limited number of applicants:

(A) references to earlier contracts awarded by the applicant for the cultivation, processing and delivery of cannabis for medical purposes with a delivery quantity of at least 50 kg per reference for the last 3 years. A reference to an order for the cultivation, processing and delivery of medical cannabis shall also apply if, with the consent of the competent authority in the country concerned, the tenderer submits directly to this body in accordance with Article 23 of the 1961 Unified Agreement on Narcotic Drugs A variety of different performance receivers have been delivered and the total delivery quantity has amounted to at least 50 kg. The applicant will receive 10 points (maximum 40 points) per 50 kg of delivery (whether in the context of one or more orders).

(B) references to the cultivation, processing and supply of medicinal plants (without cannabis) with a delivery quantity of at least 50 kg per reference over the last three years (whether in the case of a single order or several contracts) Points (maximum score 20 points).

C) If more than 10 applicants receive a score of more than 60, the selection is based on the highest total delivery quantity in the last three years according to lit. A), according to lit. b).

D) If fewer than 10 applicants receive a score of 60, the selection is based on the highest total delivery quantity in the last three years according to lit. A), according to lit. b).

II.2.10)Information about variants / alternative offers

Variants / alternative offers are permitted: no

II.2.11) Informationon options

Options: no
II.2.12)Information about electronic catalogs

II.2.1)Information about European Union funds

The contract is linked to a project and / or program financed by the EU: no
II.2.1)Additional information
II.2)Description

II.2.1)Title attributed to the contract:

Cultivation, further processing, storage, packaging and delivery of cannabis for medical purposes in a secure inhouse plantation in Germany.

Lot No: 7

II.2.2)Additional CPV code (s)

03117120

II.2.3)Place of performance

NUTS code: DEA22

II.2.4)Description of the sourcing:

Cultivation, processing, storage, packaging and delivery of cannabis (type 2): delivery period 2019 to 2022, delivery volume approx. 200 kg per year.

II.2.5)Award criteria

The price is not the only supplementary criterion; All criteria are listed in the procurement documents only
II.2.6)Estimated value

II.2.7)Duration of the contract or framework agreement or of the dynamic purchasing system

Duration in months:
This contract can be extended: no

II.2.9)Indication about the number of operators who will be invited to tender or to participate

Planned number of candidates: 10
Objective criteria for selecting the limited number of applicants:

(A) references to earlier contracts awarded by the applicant for the cultivation, processing and delivery of cannabis for medical purposes with a delivery quantity of at least 50 kg per reference for the last 3 years. A reference to an order for the cultivation, processing and delivery of medical cannabis shall also apply if, with the consent of the competent authority in the country concerned, the tenderer submits directly to this body in accordance with Article 23 of the 1961 Unified Agreement on Narcotic Drugs A variety of different performance receivers have been delivered and the total delivery quantity has amounted to at least 50 kg. The applicant will receive 10 points (maximum of 40 points) for each 50 kg of delivery (whether for one or more orders).

(B) references to the cultivation, processing and supply of medicinal plants (without cannabis) with a delivery quantity of at least 50 kg per reference over the last three years (whether in the case of a single order or several contracts) Points (maximum score 20 points).

C) If more than 10 applicants receive a score of more than 60, the selection is based on the highest total delivery quantity in the last three years according to lit. A), according to lit. b).

D) If fewer than 10 applicants receive a score of 60, the selection is based on the highest total delivery quantity in the last three years according to lit. A), according to lit. b).

II.2.10)Information about variants / alternative offers

Variants / alternative offers are permitted: no

II.2.11) Informationon options

Options: no
II.2.12)Information about electronic catalogs

II.2.1)Information about European Union funds

The contract is linked to a project and / or program financed by the EU: no
II.2.1)Additional information
II.2)Description

II.2.1)Title attributed to the contract:

Cultivation, further processing, storage, packaging and delivery of cannabis for medical purposes in a secure inhouse plantation in Germany.

Lot No: 8

II.2.2)Additional CPV code (s)

03117120

II.2.3)Place of performance

NUTS code: DEA22

II.2.4)Description of the sourcing:

Cultivation, processing, storage, packaging and delivery of cannabis (type 2): delivery period 2020 to 2022, delivery volume approx. 200 kg per year.

II.2.5)Award criteria

The price is not the only supplementary criterion; All criteria are listed in the procurement documents only
II.2.6)Estimated value

II.2.7)Duration of the contract or framework agreement or of the dynamic purchasing system

Duration in months:
This contract can be extended: no

II.2.9)Indication about the number of operators who will be invited to tender or to participate

Planned number of candidates: 10
Objective criteria for selecting the limited number of applicants:

(A) references to earlier contracts awarded by the applicant for the cultivation, processing and delivery of cannabis for medical purposes with a delivery quantity of at least 50 kg per reference for the last 3 years. A reference to an order for the cultivation, processing and delivery of medical cannabis shall also apply if, with the consent of the competent authority in the country concerned, the tenderer submits directly to this body in accordance with Article 23 of the 1961 Unified Agreement on Narcotic Drugs A variety of different performance receivers have been delivered and the total delivery quantity has amounted to at least 50 kg. The applicant will receive 10 points (maximum of 40 points) for each 50 kg of delivery (whether for one or more orders).

(B) references to the cultivation, processing and supply of medicinal plants (without cannabis) with a delivery quantity of at least 50 kg per reference over the last three years (whether in the case of a single order or several contracts) Points (maximum score 20 points).

C) If more than 10 applicants receive a score of more than 60, the selection is based on the highest total delivery quantity in the last three years according to lit. A), according to lit. b).

D) If fewer than 10 applicants receive a score of 60, the selection is based on the highest total delivery quantity in the last three years according to lit. A), according to lit. b).

II.2.10)Information about variants / alternative offers

Variants / alternative offers are permitted: no

II.2.11) Informationon options

Options: no
II.2.12)Information about electronic catalogs

II.2.1)Information about European Union funds

The contract is linked to a project and / or program financed by the EU: no
II.2.1)Additional information
II.2)Description

II.2.1)Title attributed to the contract:

Cultivation, further processing, storage, packaging and delivery of cannabis for medical purposes in a secure inhouse plantation in Germany.

Lot No: 9

II.2.2)Additional CPV code (s)

03117120

II.2.3)Place of performance

NUTS code: DEA22

II.2.4)Description of the sourcing:

Cultivation, processing, storage, packaging and delivery of cannabis (type 3): delivery period 2019 to 2022, delivery volume approx. 200 kg per year.

II.2.5)Award criteria

The price is not the only supplementary criterion; All criteria are listed in the procurement documents only
II.2.6)Estimated value

II.2.7)Duration of the contract or framework agreement or of the dynamic purchasing system

Duration in months:
This contract can be extended: no

II.2.9)Indication about the number of operators who will be invited to tender or to participate

Planned number of candidates: 10
Objective criteria for selecting the limited number of applicants:

(A) references to earlier contracts awarded by the applicant for the cultivation, processing and delivery of cannabis for medical purposes with a delivery quantity of at least 50 kg per reference for the last 3 years. A reference to an order for the cultivation, processing and delivery of medical cannabis shall also apply if, with the consent of the competent authority in the country concerned, the tenderer submits directly to this body in accordance with Article 23 of the 1961 Unified Agreement on Narcotic Drugs A variety of different performance receivers have been delivered and the total delivery quantity has amounted to at least 50 kg. The applicant will receive 10 points (maximum 40 points) per 50 kg of delivery (whether in the context of one or more orders).

(B) references to the cultivation, processing and supply of medicinal plants (without cannabis) with a delivery quantity of at least 50 kg per reference over the last three years (whether in the case of a single order or several contracts) Points (maximum score 20 points).

C) If more than 10 applicants receive a score of more than 60, the selection is based on the highest total delivery quantity in the last three years according to lit. A), according to lit. b).

D) If fewer than 10 applicants receive a score of 60, the selection is based on the highest total delivery quantity in the last three years according to lit. A), according to lit. b).

II.2.10)Information about variants / alternative offers

Variants / alternative offers are permitted: no

II.2.11) Informationon options

Options: no
II.2.12)Information about electronic catalogs

II.2.1)Information about European Union funds

The contract is linked to a project and / or program financed by the EU: no
II.2.1)Additional information
II.2)Description

II.2.1)Title attributed to the contract:

Cultivation, further processing, storage, packaging and delivery of cannabis for medical purposes in a secure inhouse plantation in Germany.

Lot No: 10

II.2.2)Additional CPV code (s)

03117120

II.2.3)Place of performance

NUTS code: DEA22

II.2.4)Description of the sourcing:

Cultivation, processing, storage, packaging and delivery of cannabis (type 3): delivery period 2021 to 2022, delivery quantity approx. 200 kg per year.

II.2.5)Award criteria

The price is not the only supplementary criterion; All criteria are listed in the procurement documents only
II.2.6)Estimated value

II.2.7)Duration of the contract or framework agreement or of the dynamic purchasing system

Duration in months:
This contract can be extended: no

II.2.9)Indication about the number of operators who will be invited to tender or to participate

Planned number of candidates: 10
Objective criteria for selecting the limited number of applicants:

(A) references to earlier contracts awarded by the applicant for the cultivation, processing and delivery of cannabis for medical purposes with a delivery quantity of at least 50 kg per reference for the last 3 years. A reference to an order for the cultivation, processing and delivery of medical cannabis shall also apply if, with the consent of the competent authority in the country concerned, the tenderer submits directly to this body in accordance with Article 23 of the 1961 Unified Agreement on Narcotic Drugs A variety of different performance receivers have been delivered and the total delivery quantity has amounted to at least 50 kg. The applicant will receive 10 points (maximum 40 points) per 50 kg of delivery (whether in the context of one or more orders).

(B) references to the cultivation, processing and supply of medicinal plants (without cannabis) with a minimum quantity of 50 kg per reference over the last three years (whether in the context of one or more contracts): The applicant shall be supplied per 50 kg of delivery 5 points (maximum score 20 points).

C) If more than 10 applicants receive a score of more than 60, the selection is based on the highest total delivery quantity in the last three years according to lit. A), according to lit. b).

D) If fewer than 10 applicants receive a score of 60, the selection is based on the highest total delivery quantity in the last three years according to lit. A), according to lit. b).

II.2.10)Information about variants / alternative offers

Variants / alternative offers are permitted: no

II.2.11) Informationon options

Options: no
II.2.12)Information about electronic catalogs

II.2.1)Information about European Union funds

The contract is linked to a project and / or program financed by the EU: no
II.2.1)Additional information

Section III: Legal, economic, financial and technical information

III.1)Conditions for participation

III.1.1)Empowerment in professional or professional capacity, including requirements relating to the professional or trade registers

Listing and brief description of the conditions:

The tenderer’s declaration of entry in a professional or trade register or other proof of the professional qualification required in the State in which the applicant is established.

The client reserves the right to submit the following documents within the framework of the appraisal of the participation requests to a separate request:

– Local business register,

– a certificate from the competent social security authorities that social security contributions are paid in accordance with the regulations,

– the certificate of the competent professional association that the tenderer is a member there and who is contributing,

– Tax exemption certificate issued by the tax office,

– Declaration on the grounds of exclusion pursuant to §§ 123, 124 GWB.

III.1.2)Economic and financial capacity

List and brief description of the suitability criteria:

– the total turnover of the applicant in the last three financial years, if any.

– information on the applicant’s turnover in the area of ​​the cultivation, processing and delivery of cannabis for medical purposes, where available.

– an indication of the applicant’s turnover in the area of ​​the cultivation, processing and supply of medicinal plants during the last three financial years, where available.

– an indication of the existence of a professional or occupational liability insurance amounting to EUR 5 million (twice a year maximized) or the tenderer’s assurance to conclude such insurance in the case of the subdivision.

– submit the candidates’ annual accounts, if their publication is legally required by the applicant.

– indication that the financing of the contract is to be secured (financing by equity, shareholder loans, loans from a credit institution or similar), as well as the insurer’s insurance A corresponding commitment from the financing credit institution.

III.1.3)Technical capacity and professional capacity

List and brief description of the suitability criteria:

Information on the tenderer ‘s previous contracts for the cultivation, processing and delivery of medical cannabis in the last three years, if any (list showing the contract value, the delivery quantity, the delivery period and the recipient of the service and, where available, Country competent authority in accordance with Article 23 of the “Unity Convention 1961 on Narcotics” concluded in New York on 30 March 1961).

– information on the tenderer’s references to contracts for the cultivation, processing and delivery of medicinal plants carried out in the past three years, where available (list showing the contract value, the delivery volume, the delivery period and the beneficiary).

– indication of the technical personnel to be used by the tenderer in connection with the service.

– information on the equipment, equipment and technical equipment of the contractors to carry out the contract.

Minimum standards required:

At least one reference for the purpose of cultivation, processing and delivery of medicinal cannabis (minimum quantity of 50 kg) or a contract for the cultivation, processing and supply of medicinal plants (minimum 50 kg) for the last three years. A reference to a contract for the planting and delivery of medical cannabis shall also apply if, with the consent of the competent authority in the country concerned, the tenderer submits directly to a variety of different beneficiaries, in accordance with Article 23 of the “Unified Convention on Narcotic Drugs” And the total quantity delivered is at least 50 kg. As a reference about an order to cultivate,

III.1.5)Information about reserved contracts
III.2)Conditions relating to the contract

III.2.2)Conditions relating to the performance of the contract:

Permission according to § 3 Drugs Act.

Permission according to § 13 Arzneimittelgesetz.

III.2.3)Personnel responsible for execution of the contract

Obligation to indicate the names and professional qualifications of the persons responsible for the execution of the contract

Section IV: Procedure

IV.1)Description

IV.1.1) Type ofprocedure

negotiated procedure
IV.1.3)Information about a framework agreement or a dynamic purchasing system (DPS)

IV.1.4) Informationabout reduction of the number of operators or solutions to be taken during the negotiation or dialogue

The succession of the procedure in successive stages in order to gradually reduce the number of solutions to be discussed and / or the tenders to be negotiated
IV.1.5)Information about a negotiated procedure
IV.1.6)Information about electronic auction

IV.1.8) Informationabout the Procurement Agreement (GPA)

The contract is covered by the Procurement Agreement: no
IV.2)Administrative informationIV.3)
IV.2.1)Previous publication concerning this procedure

IV.2.2)Time-limit for receipt of tenders or requests to participate

Day: 05/06/2017
Local Time: 12:00

IV.2.3)Time-limit for receipt of tenders or requests to participate:

Day: 28/06/2017

IV.2.4)Language (s) in which tenders or requests to participate may be drawn up:

German

IV.2.6)Minimum time frame during which the tenderer must maintain the tender

Duration in months: 6 (from the date of receipt of tenders)
IV.2.7)Conditions for opening tenders

Section VI: Additional information

VI.1)Information about a return of the contract

This is a recurring job: yes
Estimated timing for further notices:

02/01/2021.

VI.2)Information about electronic work processes

No. VI.3)Additional information:

Details of the invitation to tender and of the documents to be submitted can be found in the tender form “Procurement procedure for the cultivation, processing, storage, packaging and delivery of cannabis for medical purposes, here: Invitation to submit applications for participation”, which forms part of the tender documents.

This procurement procedure will be carried out electronically on the website of the eVergabe platform ( www.evergabe-online.de ).

Please note that the free download of the tender documents is only for a first view. In order to participate in the tender, you must apply for participation. Only if you apply for the tender, you will be actively informed about any changes to the tender documents and will be able to ask questions about the tender or receive the answers.

Any legal or professional questions concerning the award procedure or the tender documents must be addressed to the eVergabe platform.

VI.4)Procedures for appeal / review

VI.4.1) Bodyresponsible for appeal procedures

Awarding Office of the
Confederation Villemombler Straße 76
Bonn
53123
Germany
VI.4.2)Body responsible for appeal procedures

VI.4.3)Lodging of appeals

Precise information on the time limits for lodging appeals:

Section 160 GWB

(1) The awarding authority shall initiate a review procedure only upon request.

2. Any undertaking which is interested in the public contract or the concession and who asserts an infringement in its rights pursuant to Article 97 (6) by not observing public procurement rules shall have the right to submit applications. It must be shown that the alleged infringement of the public procurement rules has caused or is likely to result in damage to the company.

(3) The application is inadmissible in so far as:

1. the applicant has recognized the alleged infringement of public procurement rules before submitting the request for review and has not complained to the contracting authority within a period of ten calendar days; The expiry of the time limit pursuant to Section 134 (2) shall remain unaffected,

2. Infringements of public procurement rules which are discernible on the basis of the notice shall not be complained to the contracting authority not later than the expiry of the period set out in the notice of invitation to tender,

3. Infringements of the public procurement rules, which are only recognizable in the tender documents, are not complained against the contracting authority at the latest until the expiry of the deadline for the application or tender,

4. have passed more than 15 calendar days after receipt of the notice of the contracting authority not to remedy a complaint.

VI.4.4)Service from which information about the lodging of appeals may be obtained

Awarding Office of the
Confederation Villemombler Straße 76
Bonn
53123
Germany

VI.5)Date of dispatch of this notice:

04/04/2017


Leave a comment

Legalize It, a Zurich-based group, has launched a campaign to legally regulate cannabis across Switzerland

Could Switzerland Become the First European Country to Legally Regulate Cannabis?

Nine years after a Swiss referendum failed to gain public approval for cannabis legalisation, a campaign group has reignited the movement for reform.

Legalize It, a Zurich-based group, has launched a campaign to legally regulate cannabis across Switzerland. The objectives of the initiative, Legalize It describes, are three-fold: to allow adults the “freedom and right to consume cannabis”, to prevent those who seek cannabis from having to purchase from the “black market”, and to ensure increased investment into drug use prevention, related research, and social security. The funds for such investment, the group says, will be acquired from the taxation of cannabis sales, and savings on law enforcement expenditure.

The campaign comes in the form of a federal popular initiative, a legislative instrument by which Swiss citizens can suggest changes in the law. If the proposal garners 100,000 valid signatures from Swiss citizens, it will be put forward for debate by the Federal Council, the country’s highest executive authority, and the Federal Assembly, the highest legislative authority.

The Federal Palace of Switzerland. Source: Wikimedia Commons

The cultivation, sale, and use of cannabis are outlawed in Switzerland in almost all cases, however punishment for minor possession is relatively light. Under the current law, an adult found to be in possession of up to 10 grams of cannabis will be fined 100 Swiss francs (£78), and will not be criminally prosecuted. In 2015, there were a total of 18,366 such fines across Switzerland.

Around three percent of adult Swiss residents use cannabis monthly, and almost 40 per cent of adults claim to have used it at least once in their life, according to Addiction Monitoring in Switzerland.

An attempt to legally regulate cannabis was resoundingly opposed by the public in a 2008 referendum, in which 63 per cent of voters opposed the measure. However, the public’s view on the subject has changed over the past decade, according to Nino Forrer, spokesperson for Legalise It.

“Many other countries have legalised or decriminalised cannabis in some form since 2008 and the results are good […] Based on this new data, the Swiss people will see more benefits than harms in legalising cannabis, I’m sure”, Forrer told TalkingDrugs.

“There has not been a massive rise in cannabis consumption among the youth [in places that have legalised cannabis], no surge in traffic accidents, no massive increased health costs. Instead, many jurisdictions have put the extra money from cannabis taxes into public healthcare, infrastructure, and schools in order to improve the standard of living for their people.”

A legal cannabis crow in Colorado. Source: Brett Levin

For example, in 2016, the US state of Colorado collected over $150 million in cannabis sale taxes, of which around $50 million was directed to school projects. Similarly, Legalize Itclaims that taxing the drug could raise 100 million Swiss francs (£78 million) each year, based on their estimates of consumption rates.

Forrer believes that the success of foreign initiatives, such as that in Colorado, may be enough for the Swiss authorities and public to support Legalize It’s new campaign – but only if the message can be effectively be delivered.

“We have had very good responses so far! Many people in Switzerland were waiting for this initiative, so they are very happy that we have started it”, Forrer told us.

“Now, we will try to inform the public as much as possible in order to gather a strong activist base all over the country. Mass media affects our perception of cannabis to a large extent, so good press is needed in order to win over the minds of Swiss people”.

If this initiative proves successful, Switzerland could become the first country in Europe to introduce a legally regulated cannabis market.

Avinash Tharoor is the Editor of TalkingDrugs. He tweets at @AvinashTharoor